[Federal Register Volume 79, Number 43 (Wednesday, March 5, 2014)]
[Notices]
[Pages 12512-12515]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-04771]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
Software for 3D Spectral Fingerprint Based Consensus Modeling Using
Orthogonal PLS and Tanimoto Similarity KNN Techniques
Description of Technology: This technology is a software tool for
improving molecular modeling. The software addresses data matrices
processed in rows instead of columns and the result of these approaches
are combined. To process data in rows, the technique uses a measure of
similarity known as ``Tanimoto Similarity'' operating on pairs of
objects. The property values of the top most similar objects are
normalized and used as coefficients to predict the property of
interest. These predictions can then be used in combination with the
predictions obtained by multivariate techniques to improve the quality
of the consensus model in comparison to the individual predictions.
Since, in the case of multivariate techniques, the information is
accessed in columns, while for the similarity based technique it is
accessed in rows, the two types of techniques provide complementary
information. Thus, more useful information can be extracted from the
same data matrix. Also contemplated is the use of consensus modeling by
letting two algorithms (PLS and KNN) operate on descriptor matrices of
different size. If each of these matrices is processed by a different
model building algorithm and a consensus model between two or more such
individual models is built, the resulting model would benefit from
both: i) the partial orthogonality of the modeling techniques and ii)
the complementarity of the information contained in 3D-SDAR matrices of
different granularity.
Potential Commercial Applications:
Drug Design
Drug Development
Competitive Advantages:
Matrix processing of molecules of biological interest
High Fit-Activity Prediction capacity
Development Stage:
Early-stage
In vitro data available
Inventors: Svetoslav H. Slavov, Jon G. Wilkes, Rick Beger, Dan A.
Buzatu, Bruce A. Pearce (all of FDA)
Publications:
1. Slavov SH, et al. \13\C NMR-distance matrix descriptors:
optimal abstract 3D space granularity for predicting estrogen
binding. J Chem Inform Model. 2012 Jul 23;52(7):1845-64. [PMID
22681591]
2. Slavov SH, et al. Complementary PLS and KNN algorithms for
improved 3D-QSDAR consensus modeling of AhR binding. J Cheminform.
2013 Nov 21;5(1):47-62. [PMID 24257141]
3. Stoyanova-Slavova IB, et al. PLS and KNN algorithms for
improved 3D-QSDAR consensus modeling of acute toxicity. Environ
Toxicol Chem. 2014 Jan 27 (Epub ahead of print). [PMID 24464801]
Intellectual Property: HHS Reference No. E-015-2014/0--Software
Materials. Patent protection is not being pursued for this
technology.
Related Technologies:
HHS Reference No. E-209-1999/1--US Patent 6,898,533 issued
24 May 2005
HHS Reference No. E-297-2001/0--US Patent 7,996,156 issued
09 Aug 2011
Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-6019;
[email protected].
Collaborative Research Opportunity: The Food and Drug
Administration is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate or commercialize Molecular Modeling/Drug Design. For
collaboration opportunities, please contact Ashley Groves at 870-
543-7956.
Multivalent, Multiple-Antigenic-Peptides for Serological Detection of
HIV-1 Groups -M, -N, -O, and HIV-2
Description of Technology: This CDC-developed invention pertains
to multivalent antigenic peptides (MAPs) that can be used in a
variety of HIV/AIDS diagnostics. There are two types of HIV: HIV-1
and HIV-2. HIV-1 is subdivided into groups M, N, and O, while HIV-2
is subdivided into subtypes A and B. Within HIV -1 group M, several
different subtypes and numerous forms of recombinant viruses exist.
To detect all types, groups, and subtypes of HIV by serological
methods, a mixture of antigens derived from different viral strains
representing different HIV types and subtypes is needed. However,
due to the competition and dilution effect, mixing multiple antigens
may reduce the amount of individual antigen bound to the solid phase
and lead to a reduction in assay sensitivity.
It is known that MAPs, which contain multiple branches of an
oligopeptide sequence, are more antigenic than the corresponding
single chain linear peptides. The MAPs encompassed by this
technology contain multiple branches of oligopeptides of different
sequences, derived from HIV-1 group M, N, O, and HIV-2. Thus,
depending on the peptide sequences incorporated, a single MAP can be
used to detect HIV-1 group M alone, HIV-2 alone, or to
simultaneously detect HIV-1 groups M, N, O, and HIV-2 with high
sensitivity and specificity.
Potential Commercial Applications:
Diagnostic test for HIV-1 and/or HIV-2 infection
Blood and plasma donation screening
HIV/AIDS surveillance and monitoring programs
Competitive Advantages:
Lateral flow assays for HIV detection and discrimination
On-site, point-of-care testing and diagnosis
Easily formulated as an ELISA kit for commercial or
research applications
Technology can be used to develop a rapid, low-cost method
of determining HIV status for home-use or low-resource settings
Development Stage: In vitro data available
Inventor: Chou-Pong Pau (CDC)
Publications:
1. Granade TC, et al. Rapid detection and differentiation of
antibodies to HIV-1 and HIV-2 using multivalent antigens and
magnetic immunochromatography testing. Clin Vaccine Immunol. 2010
Jun;17(6):1034-9. [PMID 20410326]
2. Pau C, et al. Chimeric multiple antigenic peptides for the
simultaneously detection of specific antibodies to HTV-1 groups M,
N, O, and HIV-2. J Immunol Methods. 2007 Jan 10;318(1-2):59-64.
[PMID 17169369]
[[Page 12513]]
3. Kim P and Pau CP. Comparing tandem repeats and multiple antigenic
peptides as the antigens to detect antibodies by enzyme immunoassay.
J Immunol Methods. 2001 Nov 1;257(1-2):51-4. [PMID 11687238]
Intellectual Property: HHS Reference No. E-604-2013/0--Research
Tool. Patent protection is not being pursued for this technology.
Related Technologies:
HHS Reference No. E-052-2013/0
HHS Reference No. E-053-2013/0
HHS Reference No. E-173-2013/0
HHS Reference No. E-232-2013/0
HHS Reference No. E-259-2013/0
HHS Reference No. E-294-2013/0
HHS Reference No. E-357-2013/0
HHS Reference No. E-358-2013/0
HHS Reference No. E-522-2013/0
HHS Reference No. E-555-2013/0
HHS Reference No. E-638-2013/0
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Recombinant, Multivalent Malarial Antigens for Development of
Therapeutics, Diagnostics and/or a Multistage Vaccine for Plasmodium
falciparum
Description of Technology: This CDC-generated technology relates
to a recombinant, multivalent and multi-stage malaria vaccine and,
more specifically, to antigenic proteins useful for preventing or
treating Plasmodium falciparum malarial infections. Malaria
continues to be a public health problem throughout the world and P.
falciparum is often identified as the cause of the most severe forms
of the disease. Ideally, an effective malaria vaccine would contain
a combination of key antigens/epitopes from different stages of the
pathogen's complex life-cycle. This approach to vaccination would
likely result in the induction of both humoral and cellular immunity
for optimal efficacy and a broad scope of protection.
This technology entails a multi-stage vaccine against malaria
that is effective in inhibiting reproductive growth of the parasite
within a human or animal after initial infection. Further, the
technology includes antibodies against a recombinant protein
containing antigenic epitopes to varied life-cycle stages of a
malarial Plasmodium species. These antigens and antibodies may be
useful as research tools or diagnostic reagents for the detection
and diagnosis of P. falciparum at a number of different life-cycle
stages within a biological sample.
Potential Commercial Applications:
Malaria vaccine development
Useful for malaria vaccination and surveillance programs
Military, foreign service applications
Mitigation of zoonotic disease transmission and livestock
morbidity, especially within South Asia
Competitive Advantages:
Single vaccine confers immunity against the malarial
parasite at multiple life cycle stages, increasing the chances of
neutralizing sustained infection
In vivo animal studies demonstrate vaccine efficacy
Development Stage:
In vitro data available
In vivo data available (animal)
Inventors: Altaf A. Lal (CDC), Ya-Ping Shi (CDC), Seyed P.
Hasnain (National Institute of Immunology--India)
Publication: Shi YP. Immunogenicity and in vitro protective
efficacy of a recombinant multistage Plasmodium falciparum candidate
vaccine. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1615-20. [PMID:
9990073]
Intellectual Property: HHS Reference No. E-451-2013/0--
US Patent No. 6,828,416 issued 07 Dec 2004
Various international patent applications pending or issued
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis
of Atmospheric or Aerosolized Particulate Mixtures
Description of Technology: This technology pertains to monitors
for measuring the mass concentration of ambient particulate matter
in an atmosphere containing both larger/coarser (e.g., respirable
dust) and smaller/finer (sub-micrometer particles such as diesel
particulate matter--DPM) particulate mixtures. The monitoring device
can be configured for operation with a controller unit adapted to
ionization sensor and/or light-scattering modules. The controller
translates the sensor output signal into a quantifiable value,
determining mass concentration of particulate matter within the
ionization chamber. For example, practical applications of this
monitor/analysis technology would easily extend to use in mining
operations (where both DPM and respirable dust exist in abundance),
industrial manufacturing facilities, and anywhere that frequent or
extended exposure to fuel-combustion exhaust or airborne pollution
is a concern. Further, by virtue of its ability to distinguish
``fire smoke'' from other aerosols that may be present, the device
also has significant potential for use in early-warning fire
detection.
Potential Commercial Applications:
Airborne particle monitor for mining and industrial
manufacturing operations
Addressing emissions control standards and regulations
Early-warning fire detection in locations where traditional
smoke-detector use is impractical
Competitive Advantages:
Inexpensive and simple to implement
Device provides continuous, simultaneous, and independent
measurement of both respirable dust and diesel particulate matter
(DPM) mass concentrations
Previous particulate counting technologies are both
expensive and cannot provide accurate quantification of coarse/fine
aerosol mixtures, concentrations
Development Stage:
In situ data available (on-site)
Prototype
Inventors: Charles D. Litton, Jon C. Volkwein, William H.
Schiffbauer (all of CDC)
Intellectual Property: HHS Reference No. E-240-2013/0--US Patent
No. 6,965,240 issued 27 Mar 2003
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
A Targeted Therapy for the Activated B Cell-Like Subtype of Diffuse
Large B Cell Lymphoma
Description of Technology: NIH scientists have developed novel
peptides that specifically target the activated B cell like (ABC)
subtype of diffuse large B cell lymphoma (DLBCL), which is the least
curable form of this aggressive lymphoma.
ABC DLBCL is characterized by constitutive NF-kB pathway
activation, which depends on the binding of two protein molecules,
RNF31 and RBCK1. These cell-permeable peptides compete against
endogenous RNF31, therefore inhibit the NF-kB induction pathway and
kill the malignant cells.
This technology would be a potential targeted therapy for ABC
DLBCL, and could be combined with radiation or chemotherapy for ABC
DLBCL or other cancers. Additionally, these peptides could also be
applied to treat rheumatoid arthritis, chronic autoinflammation,
systemic lupus erythematosus, Crohn's inflammatory bowel disease, or
psoriasis.
Potential Commercial Applications:
Targeted therapies for ABC DLBCL.
Combination cytotoxic chemotherapies for ABC DLBCL.
Treatment for other cancers or autoimmune/inflammatory
diseases that depend upon the function of RNF31 and RBCK1
combination.
Competitive Advantages:
Novel composition of inhibitors for ABC DLBCL.
Novel targeted drug to ABC DLBCL.
Effective therapies targeting at NF-kB pathway.
Development Stage:
Early-stage
In vitro data available
Inventors: Louis M. Staudt, Yibin Yang, Federico Bernal (all of
NCI)
Publication: Yang Y, et al. Essential Role of the Linear
Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare
Germline Polymorphisms. Cancer Discov. 2014 Feb 3 (Epub ahead of
print). [PMID 24491438]
Intellectual Property: HHS Reference No. E-035-2013/0--US
Provisional Application No. 61/789,064 filed 15 March 2013
Licensing Contact: Sabarni Chatterjee, Ph.D., MBA; 301-435-5587;
[email protected].
Collaborative Research Opportunity: The National Cancer
Institute is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate or commercialize the inhibitors of the LUBAC ubiquitin
ligase for the therapy of lymphoma and autoimmune diseases. For
collaboration
[[Page 12514]]
opportunities, please contact John D. Hewes, Ph.D. at
[email protected].
Mutation Based Control Plasmids for Standardizing Cancer Genomic
Diagnostic Assays
Description of Technology: To date, there are no widely accepted
standards and controls for multi-analyte based diagnostic assays.
The ability to compare the accuracy of different types of assay
results and to utilize in process controls is hampered by the lack
of availability of such standards/controls. Variations resulting
from different platforms, methodologies, and bioinformatics analyses
therefore create error in the interpretation of assay reports and
different results may occur when testing for the presence or absence
of specific gene mutations or biomarkers.
This technology includes a library of plasmids that can be used
to test for and control for accuracy, sensitivity, and specificity
and reproducibility within an assay and across different assays or
laboratories and platforms. These standards consist of normal human
reference genomic DNA that have engineered to contain known sequence
variations representing somatic mutations of interest to cancer
management. The plasmids contain approximately 1000 bases of human
sequence. Each inserted sequence carries a specific mutation of
interest within the appropriate genomic locus and a mutation
adjacent alien barcode. The plasmids can be mixed with non-mutant
genomes to create exact variant to normal allele frequencies for
limit of detection studies. The alien barcode unequivocally
indicates the detected mutation is from the plasmid spiked into a
test human specimen. If needed for certain applications the barcode
can be left out of design.
Potential Commercial Applications:
Quantified standards for scientists to compare, optimize
and/or validate assays
Assess specificity, sensitivity, accuracy and limit
detection of artifacts during assay development
Internal in process run controls to monitor assay
performance
Competitive Advantages:
Reference materials for comparing results of assays
performed by different platforms, operators, times, and sites
Ability to uniquely distinguish plasmid control mutations
spiked directly into unknown samples by alien barcode
No limit in the number and types of mutation plasmids
introduced into the test human specimen, unlike engineered cell line
genome based mutation controls
Easy design and manufacture process
Development Stage: In vitro data available
Inventors: Chih-Jian Lih, Paul Williams, David Sims, Michele
Mehaffey (all of NCI)
Publications: Manuscripts in preparation.
Intellectual Property: HHS Reference No. E-265-2012/0--Research
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Jennifer Wong, M.S.; 301-435-4633;
[email protected]
Collaborative Research Opportunity: The National Cancer
Institute, Cancer Diagnosis Program, is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize Mutation
Based Control Plasmids for Standardizing Cancer Genomic Diagnostic
Assays. For collaboration opportunities, please contact John Hewes,
Ph.D. at [email protected].
Use of Soluble CD27 as Potential Immunotherapy and a Diagnostic and
Prognostic Serum Biomarker for Solid Tumors
Description of Technology: The present invention discloses
methods for diagnosing a patient with a solid tumor or a
predisposition to developing a solid tumor, a patient's suitability
for immunotherapy and monitor disease progression in a patient
undergoing treatment for a solid tumor, such as a prostate or
colorectal tumor, by measuring the amount of soluble CD27 (sCD27)
present in a serum sample obtained from a patient and detecting the
amount of sCD27present in the serum sample. Additionally, sCD27 can
also be developed an immunotherapeutic product. Such product will
constitute the administration of a therapeutically effective amount
of sCD27 or a functional 15 fragment thereof that is capable of
stimulating a patient's immune system.
CD27 is a tumor necrosis factor receptor. A soluble form of CD27
(sCD27), is a 32-kD protein identical to the extracellular domain of
membrane-bound CD27. CD27's role in T cell activation has been
previously demonstrated.
Potential Commercial Applications:
Serum biomarker for diagnosis, prognosis and therapeutic
response.
Can potentially be developed into an immunotherapeutic
product.
Competitive Advantages:
Potentially can be used with clinically proven platforms.
Can be developed into a minimally invasive diagnostic test
using patient's blood sample.
Development Stage:
Early-stage
In vitro data available
Inventors: Jeffrey Schlom and Jianping Huang (NCI)
Publication: Huang J, et al. Soluble CD27-pool in humans may
contribute to T cell activation and tumor immunity. J Immunol. 2013
Jun 15;190(12):6250-8. [PMID 23677477]
Intellectual Property: HHS Reference No. E-005-2011/0--US Patent
Application No. 61/824,898 filed 17 May 2013
Licensing Contact: Sabarni Chatterjee, Ph.D., MBA; 301-435-5587;
[email protected].
Collaborative Research Opportunity: The National Cancer
Institute, Laboratory of Metabolism, is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize a non-
invasive assay for the detection of colorectal cancer. For
collaboration opportunities, please contact John D. Hewes, Ph.D. at
[email protected].
The Use of alpha-4 beta-7 integrin Inhibitors To Inhibit HIV
Transmission and Infection
Description of Technology: This invention involves the use of
inhibitors of alpha-4 beta-7 ([alpha]4[beta]7) integrin to inhibit
HIV transmission/infection, as a prophylactic to inhibit onset of
the acute stage of HIV infection or to treat HIV infection. The
[alpha]4[beta]7 integrin inhibitors were previously developed for
use in other diseases, such as multiple sclerosis or inflammatory
bowel disease.
[alpha]4[beta]7 integrin is a multifaceted target for HIV
infection and recent studies indicate that it is important for
establishing HIV infection through multiple paths. Studies indicate
that: (1) CD4 T-cells present in vaginal and anal mucosa have high
levels of [alpha]4[beta]7 integrin, making CD4 T-cells permissive to
HIV infection; (2) [alpha]4[beta]7 integrin is important for cell to
cell transmission of HIV; (3) [alpha]4[beta]7 integrin is used to
dysregulate the host humoral response to HIV; and (4) HIV acts on
a4b7 integrin through an epitope in V2 loop of GP120, identified as
important for HIV vaccine protection. Additionally, primate studies
indicate that [alpha]4[beta]7 integrin inhibition of HIV infection
preserves gut-associated lymphoid tissue (GALT) generally destroyed
during the acute phase of HIV infection.
Potential Commercial Applications: Prevention and treatment of
HIV infection
Competitive Advantages:
[alpha]4[beta]7 integrin is a multifaceted target for HIV
infection
Previously developed [alpha]4[beta]7 integrin inhibitors
can be used for a new purpose
Development Stage:
Pre-clinical
In vitro data available
In vivo data available (animal)
Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci, Diana
Goode (all of NIAID)
Publications:
1. Martinelli E, et al. The frequency of
[alpha]4[beta]7\high\ memory CD4\+\ T cells
correlates with susceptibility to rectal simian immunodeficiency
virus infection. J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):325-
31. [PMID 23797688]
2. Nawaz F, et.al. The genotype of early-transmitting HIV gp120s
promotes [alpha]4[beta]7-reactivity, revealing
[alpha]4[beta]7\+\/CD4\+\ T cells as key
targets in mucosal transmission. PLoS Pathog. 2011
Feb;7(2):e1001301. [PMID 21383973]
3. Cicala C, et al. The integrin
[alpha]4[beta]7 forms a complex with cell-
surface CD4 and defines a T-cell subset that is highly susceptible
to infection by HIV-1. Proc Natl Acad Sci U S A. 2009 Dec
8;106(49):20877-82. [PMID 19933330]
4. Arthos J, et al. HIV-1 envelope protein binds to and signals
through integrin [alpha]4[beta]7, the gut
mucosal homing receptor for peripheral T cells. Nat Immunol. 2008
Mar;9(3):301-9. [PMID 18264102]
Intellectual Property:
HHS Reference No. E-055-2007/0--US Provisional Patent
Application No. 60/873,884 filed 07 Dec 2006
HHS Reference No. E-055-2007/1--US Provisional Patent
Application No. 60/920,880 filed 30 Mar 2007
[[Page 12515]]
HHS Reference No. E-055-2007/2--US Provisional Patent
Application No. 60/957,140 filed 21 Aug 2007
HHS Reference No. E-055-2007/3--PCT Patent Application No.
PCT/US2007/086663 filed 06 Dec 2007, which published as WO 2008/
140602 on 20 Nov 2008, and corresponding European Application No.
07874349.9; US Patent Application No. 12/518,035 filed 05 Jun 2009
Licensing Contact: Cristina Thalhammer-Reyero, Ph.D., M.B.A.;
301-435-4507; [email protected].
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability
or interest from parties interested in collaborative research to
further develop, evaluate or commercialize alpha-4 beta-7 integrin
inhibitors. For collaboration opportunities, please contact Bill
Ronnenberg, JD/MIP, MS at 301-451-3522 or [email protected].
Beta-Amyloid and Tau Fibril Positron Emissions Tomography (PET) Imaging
Agents
Description of Technology: The invention relates to two novel
classes of compounds useful as radioligands for in vivo imaging of
beta-amyloid fibrils, peptides and plaques in humans. Beta-amyloid
peptide deposition in the brain is a pathological feature of
Alzheimer's disease (AD). Early detection of beta-amyloid load in
patients with suspected AD is vital to initiating early treatment,
which can improve cognitive function and quality of life for many
patients. The invention describes novel derivatives of
imidazopyridinylbenzeneamine (IMPY) and benzothizolylbenzeneamine
(BTA), which demonstrate high in vitro binding affinity to human
beta-amyloid. The difference between existing IMPY compounds and the
novel derivatives is the substitution of an aryl halide with an aryl
thioether group and replacement of a sulfur group of the pyridine
ring with a nitrogen group. The new classes of compounds have the
potential of providing improved amyloid imaging agents for Positron
Emission Tomography (PET) with higher specificity for amyloid, low
background noise, better entry into the brain and improved labeling
efficiency.
Potential Commercial Applications:
Alzheimer's disease
Alzheimer's disease diagnostics
Alzheimer's disease early detection
Competitive Advantages: Specificity
Development Stage: In vitro data available
Inventors: Lisheng Cai, Victor W. Pike, Robert B. Innis (all of
NIMH)
Publications:
1. Nichols L, et al. Imaging and in vivo quantitation of beta-
amyloid: an exemplary biomarker for Alzheimer's disease? Biol
Psychiatry. 2006 May 15;59(10):940-7. [PMID 16487944]
2. Toyama H, et al. PET imaging of brain with the beta-amyloid
probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's
disease. Eur J Nucl Med Mol Imaging. 2005 May;32(5):593-600. [PMID
15791432]
3. Cai L, et al. Synthesis and evaluation of two 18F-labeled 6-iodo-
2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as
prospective radioligands for beta-amyloid in Alzheimer's disease. J
Med Chem. 2004 Apr 22;47(9):2208-18. [PMID 15084119]
Intellectual Property: HHS Reference No. E-156-2006/0--
US Patent Application 12/293,940 filed September 17, 2008
(allowed)
European Patent Application 07797254.5 filed April 19, 2007
(pending)
Related Technologies:
HHS Reference No. E-136-2008/0--``Beta Amyloid PET Imaging
Agents Based On 2-(4-phenyl)benzo[d]thiazole Derivatives''
HHS Reference Nos. E-225-2011/0 and/1--``Beta-amyloid PET
Imaging Agents Based On Benzothiazoles (BTA) Derivatives''
Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019;
[email protected].
Collaborative Research Opportunity: The National Institute of
Mental Health is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate or commercialize Alzheimer's disease diagnostics. For
collaboration opportunities, please contact Suzanne Winfield, Ph.D.
at 301-402-4324.
Dated: February 27, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-04771 Filed 3-4-14; 8:45 am]
BILLING CODE 4140-01-P